Professional Marketing briefs: October 2013
Lundbeck is readying a staff of more than 200 sales reps in anticipation of regulatory approval of its anti-depressant Brintellix, reports Bloomberg. Denmark's second-biggest drug maker could not share details regarding whether these will be in-house or contract reps, but a Takeda spokesperson tells MM&M the co-promote agreement with Takeda will leverage Lundbeck's experience working with CNS HCPs and Takeda's foundation in primary care. The FDA is scheduled to vote on the drug by October 2.
Boehringer Ingelheim is cutting jobs abroad, and sales roles are part of the headcount. PMLive reports that the company is eliminating 143 sales positions, the majority of the 178 jobs that are being cut as part of the reorganization. The remaining 35 jobs are administrative roles.